Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7381
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    94,731.27
    -979.77 (-1.02%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6841
    -0.0002 (-0.03%)
     

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Corp
Resverlogix Corp

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta.

During business proceedings at the Meeting, shareholders elected five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:

                                

Votes For

Votes Withheld

Percent For

Percent Withheld

Donald J. McCaffrey

125,007,142

7,326,179

94.46%

5.54%

Shawn Lu

126,119,539

6,213,782

95.30%

4.70%

Kelly McNeill

125,955,508

6,377,813

95.18%

4.82%

Siu Lun (Dicky) To

127,354,197

4,979,124

96.24%

3.76%

Kenneth Zuerblis

127,166,543

5,166,778

96.10%

3.90%

Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 11, 2022 (the “Information Circular”). The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.

ADVERTISEMENT

A webcast archive of the executive presentation portion of the Meeting will be available HERE.

About Resverlogix

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.

The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us:

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

www.resverlogix.com